SANUWAVE Health heads into the week after a quietly significant shift: short sellers added positions at their fastest pace in months, even as the company's largest 10% shareholder was steadily selling stock into the same tape.
Short interest has become the clearest story this week. It jumped nearly 20% over the past five sessions to reach 13.7% of the free float — the highest reading in the 60-day window tracked here, up from roughly 10.5% at the start of April. The move was not gradual; the bulk of the build came in the final two sessions of the week, with shares short crossing 813,000 by Tuesday. ORTEX's short score sits at 77.4, near the top of the range it has occupied since late April and meaningfully above the 73 handle it was running at two weeks ago. The combined signal from the score and the pace of accumulation points to an acceleration of short conviction, not just a drift.
The lending market, however, is not supporting the bear case as forcefully. Availability has tightened somewhat over the past two weeks — currently at roughly 152% of short interest, down from above 190% at end-April — but that still places it firmly in the "tight but accessible" zone. Cost to borrow is a near-flat 0.83% annualised, barely changed on the week and well below the 1% level seen in early April. There is no meaningful squeeze pressure in the borrow market right now. New shorts can add positions without friction, and the available lending pool has not been exhausted despite the week's build.
The ownership angle is where the tension sharpens. Opaleye Management — a 10% owner and SNWV's second-largest holder — sold shares across nine separate transactions between April 17 and May 1, trimming its stake from just under 966,000 shares to around 854,000. Those sales totalled approximately $2.2 million in net value and came as the stock was trading in the $16–$21 range. With short interest simultaneously rising, the combination of a major insider-level holder reducing exposure while shorts build is a dynamic worth tracking closely. That said, the sales were methodical rather than panicked, and Opaleye remains a significant top-five holder.
Analyst coverage is thin. Only Roth Capital actively follows the name, where Kyle Bauser reiterated his Buy rating at end of March but cut his price target from $53 to $47. That target sits substantially above the current $16.04 price, though the gap should be read with caution given the small analyst base and the fact that the stock has retreated significantly since that note was filed. Northland Capital initiated coverage last September at Outperform with a $55 target — both notes are now stale relative to current price levels. The bull case rests on SANUWAVE's 60% sales growth in FY2024 and improving EBITDA margins in the regenerative medicine segment. The bear case centres on Q1 seasonal applicator slowdowns, margin compression, and competitive pressure. Neither thesis has been updated with fresh analyst comment since late March.
The last earnings print (March 27) was not well-received — the stock fell 7.7% the next day and lost 9.2% over the following week. The next event is scheduled for June 11. Between now and then, the main dynamic to watch is whether short interest continues to accelerate toward the prior 52-week high in the lending pool, or whether the current pace of selling — both from Opaleye and from new shorts — generates renewed price pressure that starts to tighten the borrow market further.
See the live data behind this article on ORTEX.
Open SNWV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
